Related Experiment Video
Updated: May 30, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review
Shantashri Vaidya1, Kanjaksha Ghosh, Babu Rao Vundinti
1Department of Cytogenetics, National Institute of Immunohaematology, Parel, Mumbai, India.
Abstract:
A revolution in medical science was marked with the advent of imatinib, a site-specific drug for the management of patients with chronic myeloid leukemia (CML). Imatinib mesylate (also known as Glivec, Gleevec, STI-571, CGP57148), an orally administered 2-phenylaminopyrimidine derivative approved by FDA in 2001 for the treatment for CML, is highly effective in treating the early stages of CML, but remission induced in advanced phase was observed to be relatively short-lived. The primary cause of resistance in patients with CML is the mutations in the BCR-ABL kinase domain. This review discusses the different mechanisms leading to imatinib resistance and various treatment options to over-ride imatinib resistance.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mechanism of Antibiotic Resistance in MRSA
Differentiation of Common Myeloid Progenitor Cells

